ArticleInvestigational new drugs2026

Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.

Fen Saj et al.PubMed ↗Publisher ↗

No numbers read from the abstract.